Detalhe da pesquisa
1.
SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency.
Cell
; 187(3): 596-608.e17, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194966
2.
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
Cell
; 185(3): 447-456.e11, 2022 02 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35026151
3.
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
Cell
; 184(9): 2384-2393.e12, 2021 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794143
4.
The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant.
Int J Mol Sci
; 23(22)2022 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36430535
5.
Entorhinal grid-like codes and time-locked network dynamics track others navigating through space.
Nat Commun
; 14(1): 231, 2023 01 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720865
6.
Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein.
PLoS One
; 17(3): e0265453, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35333910
7.
No evidence for increased cell entry or antibody evasion by Delta sublineage AY.4.2.
Cell Mol Immunol
; 19(3): 449-452, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34983951
8.
Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
mBio
; 13(3): e0036422, 2022 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35467423
9.
SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination.
Cell Rep
; 39(5): 110754, 2022 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35477025
10.
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
Cell Host Microbe
; 30(8): 1103-1111.e6, 2022 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35588741
11.
Host Cell Entry and Neutralization Sensitivity of SARS-CoV-2 Lineages B.1.620 and R.1.
Viruses
; 14(11)2022 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36366573
12.
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization.
Cell Rep
; 35(3): 109017, 2021 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33857422
13.
B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination.
Cell Rep
; 37(2): 109825, 2021 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614392
14.
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
Cell Rep
; 36(3): 109415, 2021 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34270919
15.
Efficient antibody evasion but reduced ACE2 binding by the emerging SARS-CoV-2 variant B.1.640.2.
Cell Mol Immunol
; 19(9): 1067-1069, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35581351
16.
Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance.
Cell Mol Immunol
; 18(11): 2557-2559, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34635807
17.
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency.
Cell Mol Immunol
; 18(12): 2673-2675, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34697413